BRIEF—Novartis publishes positive long-term data in rare blood disorder

Switzerland’s Novartis has published long-term study safety and efficacy data from the EXTEND study of Revolade (eltrombopag) in the rare blood disorder immune thrombocytopenia (ITP).

Lead author James Bussel said the data show Revolade is: "An important oral treatment option that, by often increasing platelet counts, significantly decreased bleeding rates and reduced the need for concurrent therapies."

Data evaluating patients for up to eight years of continuous treatment were published, with a median treatment duration of 2.4 years.

The full results are published in the journal Blood.